Literature DB >> 27487741

Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.

Geunghwan Ahn1, Ann K Folkins, Jesse K McKenney, Teri A Longacre.   

Abstract

Low-grade serous carcinoma (LGSC) is an uncommon but distinct histologic subtype of ovarian carcinoma. Although the histologic features and natural history of LGSC have been described in the literature, there is no robust correlative study that has specifically addressed histologic features in correlation with clinical follow-up. To refine the criteria for invasion patterns of LGSC and determine additional clinically pertinent morphologic features of LGSC predisposing to a more aggressive clinical course, the clinicopathologic features of 52 LGSCs were evaluated and compared with those of a large series of serous borderline tumors (SBT), with and without invasive implants. To qualify for LGSC, the tumor needed to demonstrate destructive invasion, nuclear atypia that was mild to moderate at most (grade 1 or 2), and a mitotic index that did not exceed 12 mitoses per 10 high-power fields. On the basis of histologic evaluation, destructive invasion was classified into 7 primary architectural patterns: (1) micropapillary and/or complex papillary; (2) compact cell nests; (3) inverted macropapillae; (4) cribriform; (5) glandular and/or cystic; (6) solid sheets with slit-like spaces; and (7) single cells. Five-year overall survival and disease-free survival for LGSC were 82% (median, 72 mo) and 47% (median, 54 mo), respectively. All the patients with fatal outcome demonstrated tumors showing invasion with predominant patterns of cribriform glands, micropapillae and/or complex papillae, or compact cell nests. Notably, 2 of 9 patients with fatal outcome had only small foci of destructive invasion (2 and 3 mm, respectively) with compact cell nests and cribriform glands as the predominant patterns. There was no statistically significant association between pattern of invasion and disease-free survival. Classic stromal microinvasion, as defined by nondestructive stromal invasion <5 mm was identified in 52% of LGSC and was statistically more frequent in LGSC than in SBT (P<0.001). In 2 LGSCs, there were areas demonstrating an intraluminal solid proliferation of tumor cells with grade 1 or 2 nuclear atypia, which we hypothesize may represent a noninvasive form of LGSC, as similar non-invasive proliferations of morphologically low-grade serous carcinomatous cells were also identified in 8 SBTs, in either solid or compact glandular/papillary formations. One patient with this isolated noninvasive pattern in SBT developed LGSC 40 months after initial operation. LGSC was typically high stage (FIGO stages II to IV, 86%) and bilateral (68%), with multiple foci of invasion (82%). Bilaterality was significantly more common in high-stage disease (P=0.009). LGSC was associated with SBT in 84% of cases, most commonly usual type (27%), followed by cribriform (18%), micropapillary (11%), or mixed cribriform and micropapillary (7%) types; focal micropapillary and/or cribriform features were present in an additional 16%. The presence of intraluminal proliferations of cells resembling LGSC occurring in SBT should prompt additional tumor sampling and assiduous evaluation of implants (if present), as this appears to represent a form of intraepithelial carcinoma, which may be associated with invasion elsewhere.

Entities:  

Mesh:

Year:  2016        PMID: 27487741     DOI: 10.1097/PAS.0000000000000693

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

2.  Pathologic Classification of Ovarian Cancer.

Authors:  Stephanie M McGregor
Journal:  Methods Mol Biol       Date:  2022

3.  KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.

Authors:  Tao Zuo; Serena Wong; Natalia Buza; Pei Hui
Journal:  Mod Pathol       Date:  2017-10-13       Impact factor: 7.842

Review 4.  Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research.

Authors:  Angiolo Gadducci; Stefania Cosio
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 5.  Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Authors:  Abdulaziz Babaier; Hanan Mal; Waleed Alselwi; Prafull Ghatage
Journal:  Diagnostics (Basel)       Date:  2022-02-10

6.  Prognosis and Prognostic Factors of Serous Borderline Tumor-Micropapillary Variant: Retrospective Study of 200 Patients with Long-Term Follow-Up.

Authors:  Shuang-Zheng Jia; Hong-Wen Yao; Ning Li; Jun-Jun Yang; Yang Xiang; Shan Zheng; Jin-Hua Leng; Ling-Ying Wu
Journal:  J Oncol       Date:  2022-10-10       Impact factor: 4.501

7.  Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.

Authors:  Chiaki Kubo; Shigenori Nagata; Takeshi Fukuda; Rieko Kano; Takaaki Tanaka; Katsuyuki Nakanishi; Masahiko Ohsawa; Shin-Ichi Nakatsuka
Journal:  Diagn Pathol       Date:  2018-06-30       Impact factor: 2.644

8.  Three-Dimensional Cell Culture Based on Magnetic Fields to Assemble Low-Grade Ovarian Carcinoma Cell Aggregates Containing Lymphocytes.

Authors:  Caroline Natânia de Souza-Araújo; Cláudia Rodrigues Tonetti; Marcella Regina Cardoso; Liliana Aparecida Lucci de Angelo Andrade; Rodrigo Fernandes da Silva; Luís Gustavo Romani Fernandes; Fernando Guimarães
Journal:  Cells       Date:  2020-03-06       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.